Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.[ Read More ]
The intrinsic value of one OGN stock under the base case scenario is HIDDEN Compared to the current market price of 15 USD, Organon & Co. is HIDDEN
Current Assets | 4.51 B |
Cash & Short-Term Investments | 693 M |
Receivables | 1.74 B |
Other Current Assets | 2.07 B |
Non-Current Assets | 7.55 B |
Long-Term Investments | 0 |
PP&E | 1.18 B |
Other Non-Current Assets | 6.37 B |
Current Liabilities | 2.92 B |
Accounts Payable | 1.31 B |
Short-Term Debt | 9 M |
Other Current Liabilities | 1.6 B |
Non-Current Liabilities | 9.21 B |
Long-Term Debt | 8.88 B |
Other Non-Current Liabilities | 334 M |
Revenue | 6.26 B |
Cost Of Revenue | 2.52 B |
Gross Profit | 3.75 B |
Operating Expenses | 2.42 B |
Operating Income | 1.33 B |
Other Expenses | 306 M |
Net Income | 1.02 B |
Net Income | 1.02 B |
Depreciation & Amortization | 236 M |
Capital Expenditures | -261 M |
Stock-Based Compensation | 101 M |
Change in Working Capital | -155 M |
Others | 203 M |
Free Cash Flow | 538 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
8 months ago
Feb 22, 2024
|
Bought 49.9 K USD
|
Weaver Kirke
Gen. Counsel & Corp. Secy. |
+ 2720
|
18.3599 USD |
3 years ago
Aug 19, 2021
|
Bought 101 K USD
|
Francisco Ma. Fatima
Director |
+ 3000
|
33.79 USD |